Description
MUC1 is a mucin glycoprotein that is overexpressed on the surface of many cancer cells, including colorectal tumors. MUC1-targeted therapies utilize immunotherapeutic approaches to generate immune responses against cancer cells displaying this antigen.
Mechanism of Action
These treatments work by training the immune system to recognize and attack cells expressing the MUC1 protein through vaccine-based approaches or adoptive cell transfer methods. The immune response targets the aberrantly expressed MUC1 on tumor cells while sparing normal tissues.
Side Effects
Injection site reactions
Fatigue
Fever
Flu-like symptoms
Muscle aches
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04842812
med_phase_prefix1
Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
China